Secure tracking of tablets
    2.
    发明授权
    Secure tracking of tablets 有权
    平板电脑的安全追踪

    公开(公告)号:US08715725B2

    公开(公告)日:2014-05-06

    申请号:US13010101

    申请日:2011-01-20

    IPC分类号: G01B11/02 A61K9/44 G01B11/24

    摘要: The present invention relates to a verification method for tracking and tracing tablets, particularly pharmaceutical tablets. It further relates to a visible secure marking or information that is a part of such tablet (10). The invention further relates to tablets suitable for such verification method, processes for manufacturing such tablets, and methods for reading the information.

    摘要翻译: 本发明涉及用于跟踪和追踪片剂,特别是药物片剂的验证方法。 它还涉及作为这种片剂(10)的一部分的可见的安全标记或信息。 本发明还涉及适用于这种验证方法的片剂,制造这种片剂的方法以及读取该信息的方法。

    Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
    3.
    发明授权
    Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process 有权
    具有抗肥胖活性的药物组合物,其包含纯奥利司他及其制备方法的预混物

    公开(公告)号:US08685449B2

    公开(公告)日:2014-04-01

    申请号:US13576606

    申请日:2010-02-01

    申请人: Mario Atilio Los

    发明人: Mario Atilio Los

    IPC分类号: A61K9/44

    摘要: Pharmaceutical compositions with anti-obesity activity that act peripherally are provided, which comprise a premixture made up of pure orlistat as the active ingredient and other components that afford the premixture stability and suitable physical properties for simply preparing compositions for oral use with convenient dosage flexibility; and optionally necessary thickening, flavouring and colouring agents. A method for preparing said compositions is also provided. The orlistat content in the premixture is less than 20% of the total weight of the mass, preferably between 12 and 17%.The pharmaceutical composition can be formulated indistinctively from the premixture both as grooved tablets and powder for suspension.

    摘要翻译: 提供了具有外周作用的具有抗肥胖活性的药物组合物,其包含由纯奥利司他作为活性成分制成的预混合物和提供预混合物稳定性和合适的物理性质的简单制备用于口服使用的组合物的方便剂量灵活性的预混剂; 和任选需要的增稠剂,调味剂和着色剂。 还提供了制备所述组合物的方法。 预混物中的奥利司他含量小于质量总重量的20%,优选在12至17%之间。 药物组合物可以与预混合物不同的形式配制成凹槽片剂和用于悬浮的粉末。

    Pharmaceutical tablets with diffractive microstructure and compression tools for producing such tablets
    9.
    发明申请
    Pharmaceutical tablets with diffractive microstructure and compression tools for producing such tablets 有权
    具有衍生微结构的药物片剂和用于生产这种片剂的压缩工具

    公开(公告)号:US20100143467A1

    公开(公告)日:2010-06-10

    申请号:US12308484

    申请日:2007-06-12

    IPC分类号: A61K9/44 B29C43/02 G03F7/20

    摘要: A tablet (4) for pharmaceutical use has on at least one part of its surface a diffractive microstructure (11) which generates diffraction effects which can be perceived in the visible spectral range and which serve as visual safety feature. The tablet (4) consists of a plurality of individual powder particles, where the diffractive microstructures (11) are impressed into the surface of the individual powder particles. A compression tool (1, 1a, 1b, 3) to produce such tablets (4) has on one pressing surface of the compression tool (1, 1a, 1b, 3) micro-structures (11), where said microstructures (11) have dimensions which are smaller than the dimensions of the individual crystallites (30) of the material of the pressing surface of the compression tool (1, 1a, 1b, 3). The micro-structures (11) of the compression tool can be produced for example by ion etching or by imprinting.

    摘要翻译: 用于药物用途的片剂(4)在其表面的至少一部分上具有衍生微结构(11),其衍生效应可以在可见光谱范围内被感知并且用作视觉安全特征。 片剂(4)由多个单独的粉末颗粒组成,其中衍射微结构(11)被压入单个粉末颗粒的表面。 用于制造这种片剂的压缩工具(1,1a,1b,3)在压缩工具(1,1a,1b,3)的一个挤压表面上具有微结构(11),其中所述微结构(11) 具有比压缩工具(1,1a,1b,3)的按压表面的材料的各个微晶(30)的尺寸小的尺寸。 压缩工具的微结构(11)可以例如通过离子蚀刻或压印来制造。